115 related articles for article (PubMed ID: 25884575)
1. Mathematical modelling of tumour volume dynamics in response to stereotactic ablative radiotherapy for non-small cell lung cancer.
Tariq I; Humbert-Vidan L; Chen T; South CP; Ezhil V; Kirkby NF; Jena R; Nisbet A
Phys Med Biol; 2015 May; 60(9):3695-713. PubMed ID: 25884575
[TBL] [Abstract][Full Text] [Related]
2. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
[TBL] [Abstract][Full Text] [Related]
3. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm.
Latifi K; Oliver J; Baker R; Dilling TJ; Stevens CW; Kim J; Yue B; Demarco M; Zhang GG; Moros EG; Feygelman V
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1108-13. PubMed ID: 24529716
[TBL] [Abstract][Full Text] [Related]
4. Correlation of dose computed using different algorithms with local control following stereotactic ablative radiotherapy (SABR)-based treatment of non-small-cell lung cancer.
Chetty IJ; Devpura S; Liu D; Chen D; Li H; Wen NW; Kumar S; Fraser C; Siddiqui MS; Ajlouni M; Movsas B
Radiother Oncol; 2013 Dec; 109(3):498-504. PubMed ID: 24231237
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
6. Modelling and Bayesian adaptive prediction of individual patients' tumour volume change during radiotherapy.
Tariq I; Chen T; Kirkby NF; Jena R
Phys Med Biol; 2016 Mar; 61(5):2145-61. PubMed ID: 26907478
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes.
Tekatli H; Senan S; Dahele M; Slotman BJ; Verbakel WF
Radiother Oncol; 2015 Oct; 117(1):64-70. PubMed ID: 26472316
[TBL] [Abstract][Full Text] [Related]
8. Variation in Lung Tumour Breathing Motion between Planning Four-dimensional Computed Tomography and Stereotactic Ablative Radiotherapy Delivery and its Dosimetric Implications: Any Role for Four-dimensional Set-up Verification?
Ruben JD; Seeley A; Panettieri V; Ackerly T
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):21-7. PubMed ID: 26432188
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus TomoTherapy.
Xhaferllari I; El-Sherif O; Gaede S
J Appl Clin Med Phys; 2016 Sep; 17(5):329-340. PubMed ID: 27685129
[TBL] [Abstract][Full Text] [Related]
10. Gross tumour volume variations in primary non-small-cell lung cancer during the course of treatment with stereotactic body radiation therapy.
Gunter T; Ali I; Matthiesen C; Machiorlatti M; Thompson D; Algan O
J Med Imaging Radiat Oncol; 2014; 58(3):384-91. PubMed ID: 24592817
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.
Loganadane G; Martinetti F; Mercier O; Krhili S; Riet FG; Mbagui R; To H; Le Péchoux C; Levy A
Cancer Treat Rev; 2016 Nov; 50():240-246. PubMed ID: 27768919
[TBL] [Abstract][Full Text] [Related]
12. Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription.
Zindler JD; Thomas CR; Hahn SM; Hoffmann AL; Troost EG; Lambin P
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26476075
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric impact of breathing motion in lung stereotactic body radiotherapy treatment using intensity modulated radiotherapy and volumetric modulated arc therapy [corrected].
Rao M; Wu J; Cao D; Wong T; Mehta V; Shepard D; Ye J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e251-6. PubMed ID: 22365622
[TBL] [Abstract][Full Text] [Related]
14. [Current Status of Stereotactic Ablative Radiotherapy (SABR) for Early-stage
Non-small Cell Lung Cancer].
Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2016 Jun; 19(6):389-93. PubMed ID: 27335303
[TBL] [Abstract][Full Text] [Related]
15. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
17. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
[TBL] [Abstract][Full Text] [Related]
18. Variations of target volume definition and daily target volume localization in stereotactic body radiotherapy for early-stage non-small cell lung cancer patients under abdominal compression.
Han C; Sampath S; Schultheisss TE; Wong JYC
Med Dosim; 2017 Summer; 42(2):116-121. PubMed ID: 28433482
[TBL] [Abstract][Full Text] [Related]
19. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
[TBL] [Abstract][Full Text] [Related]
20. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.
Murray LJ; Thompson CM; Lilley J; Cosgrove V; Franks K; Sebag-Montefiore D; Henry AM
Phys Med Biol; 2015 Feb; 60(3):1237-57. PubMed ID: 25590229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
